PubMed Health⌕ Search

PubMed · 12659165

Multiple relaxation pathways in push-pull polyenes.

Abstract

Subpicosecond absorption and gain spectroscopy are used to investigate the excited-state behavior of push-pull polyenes made of a diethylthiobarbituric acid electron-acceptor group and a dibutylaniline electron-donor group linked by a pi-conjugated chain. Four polyenes of increasing length, ranging from n = 2 to 5 double bonds, are compared. The relaxation path and relaxation kinetics are studied in dioxane and in cyclohexane, a polar and a nonpolar solvent, respectively. In dioxane, the results provide evidence for the formation of an emissive transient state on an ultrashort time scale (2-3 ps) attributed to a charge transfer (CT) state. The regular shift of the gain peak of this transient state with increase in the chain length (ca. 100 nm per added double bond) indicates that its structure is similar to that of a cyanine, i.e. with a fully conjugated polyenic chain. Its lifetime ranges from a few tens to a few hundreds of picoseconds depending on the chain length. When the number of double bonds increases from n = 2 to 3, the lifetime increases, then decreases continuously for longer chains. In cyclohexane, where the transient CT state is not formed, the decay of the initial excited state follows the same trend when the chain length increases but the lifetimes are shorter than that of the CT state in dioxane. In both solvents, the characterization of long-lived photoproducts by synchronizing two low repetition-rate subpicosecond laser systems demonstrates a change in the relaxation route as the chain length increases. Isomerization occurs for n = 2, whereas intersystem crossing to the triplet state occurs for n = 4. The change in the relaxation channel is observed for n = 3 in both solvents with however a solvent-dependent behavior. In dioxane, relaxation to the triplet state is already observed for n = 3, while an intermediate regime with a relaxation directly to the ground state is observed in cyclohexane. The photophysics of the studied push-pull polyenes is tentatively compared to that of polymethine cyanines and substituted carotenoids.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Damien Laage, Pascal Plaza, Mireille Blanchard-Desce, Monique M Martin. 2002. Multiple relaxation pathways in push-pull polyenes.. https://doi.org/10.1039/b203201p

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗